Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

Venetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated the safety and efficacy of Ven and dexamethasone (VenDex) combination in patients with t(11;14) positive relapsed/refractory (R/R) multiple...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Kaufman, Jonathan L., Gasparetto, Cristina, Schjesvold, Fredrik H., Moreau, Philippe, Touzeau, Cyrille, Facon, Thierry, Boise, Lawrence H., Jiang, Yanwen, Yang, Xiaoqing, Dunbar, Fengjiao, Vishwamitra, Deeksha, Unger, Stefanie, Macartney, Tammy, Pesko, John, Yu, Yao, Salem, Ahmed Hamed, Ross, Jeremy A., Hong, Wan‐Jen, Maciag, Paulo C., Pauff, James M., Kumar, Shaji
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7986778/
https://ncbi.nlm.nih.gov/pubmed/33368455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.26083
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados